FMP

FMP

Enter

BPMC - Blueprint Medicines ...

Financial Summary of Blueprint Medicines Corporation(BPMC), Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically def

photo-url-https://financialmodelingprep.com/image-stock/BPMC.png

Blueprint Medicines Corporation

BPMC

NASDAQ

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

102.39 USD

-0.32 (-0.313%)

About

ceo

Ms. Kathryn Haviland

sector

Healthcare

industry

Biotechnology

website

https://www.blueprintmedicines.com

exchange

NASDAQ

Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU...

CIK

0001597264

ISIN

US09627Y1091

CUSIP

09627Y109

Address

45 Sidney Street

Phone

617 374 7580

Country

US

Employee

645

IPO Date

Apr 30, 2015

Summary

CIK

0001597264

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

09627Y109

ISIN

US09627Y1091

Country

US

Price

102.39

Beta

0.65

Volume Avg.

728.89k

Market Cap

6.41B

Shares

-

52-Week

43.89-111.02

DCF

46.94

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-21.24

P/B

-

Website

https://www.blueprintmedicines.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BPMC News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep